In vitro and in vivo proof-of-concept studies of extracellular protein degradation using novel M6PR-targeting chimeras (MTACs)

被引：0
|
作者：
Molz, Lisa [1 ]
Liu, Hu [1 ]
Zhu, Nanqun [1 ]
Karra, Srinivasa [1 ]
Tozzo, Effie [1 ]
机构：
[1] Avilar Therapeut, Waltham, MA USA
来源：
JOURNAL OF IMMUNOLOGY | 2024年 / 212卷 / 01期
关键词：
D O I：
10.4049/jimmunol.212.supp.1409.6012
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：2
相关论文
共 3 条
  • [1] Targeting a6GABAA receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal models
    Lee, Ming Tatt
    Mouri, Akihiro
    Kubota, Hisayoshi
    Lee, Hsin-Jung
    Chang, Man-Hsin
    Wu, Chen-Yi
    Knutson, Daniel E.
    Mihovilovic, Marko
    Cook, James
    Sieghart, Werner
    Nabeshima, Toshitaka
    Chiou, Lih-Chu
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 150
  • [2] Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC)
    Sinha, Ranjeet Kumar
    Burnier, Laurent
    Gupta, Naveen
    Xu, Xiao
    Kupriyanov, Sergey
    Martin, Greg
    Mosnier, Laurent O.
    Griffin, John H.
    BLOOD, 2014, 124 (21)
  • [3] Novel R41Q-and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke
    Sinha, Ranjeet Kumar
    Wang, Yaoming
    Zhao, Zhen
    Fernandez, Jose A.
    Gupta, Naveen
    Xu, Xiao
    Martin, Greg
    Kupriyanov, Sergey
    Mosnier, Laurent O.
    Zlokovic, Berislav
    Griffin, John H.
    BLOOD, 2016, 128 (22)
1